Ryanodine receptors (RyRs) are ion channels that regulate the intracellular flow of calcium in nearly all cell types. Because of their central role in human biology, RyRs are promising therapeutic targets that have been linked to a wide range of indications including serious cardiovascular disorders and skeletal myopathies.
Our novel class of small molecule investigational therapeutics called Rycals® are designed to repair RyRs which are essential for muscle function. Leaky receptors, which allow calcium ions to abnormally flow from the sarcoplasmic reticula into the cytoplasm, contribute to the progression of life-threatening cardiovascular and skeletal muscle diseases.